Compare Cassava Sciences Inc (FLNA) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Logitech International SA — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Logitech International SA trades at $100.97 (market cap $14.46B). The key difference: Logitech International SA is far larger — about 367× Cassava Sciences Inc's market cap, and Logitech International SA pays a 1.63% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Logitech International SA for 92 Days on average.
| FLNA | LOGI | |
|---|---|---|
Market Cap | $39.40M | $14.46B |
Volume | 759,018 | 349,547 |
Sector | Health | Technology |
52-Week High | $4.64 | $126.69 |
52-Week Low | $0.68 | $85.84 |
Typical Hold Time | 37 Days | 92 Days |
Enterprise Value | -$43.28M | $12.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Logitech (LOGI) trades at $102.18, down slightly (-0.22%) on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 16.28% net income margin and 35.29% ROE, supported by recent earnings beats. Recent news highlights product launches like the Zone Vibe Pro headset and a partnership with SEGA for Crazy Taxi: World Tour, indicating active business development.
The outlook is cautiously optimistic, with a consensus price target of $107 offering potential upside. Key opportunities include sustained earnings growth and new product cycles, while risks involve competitive pressures in the peripheral market and potential supply chain disruptions, as noted by the CEO addressing chip shortages (WSJ, 2026-09-30).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
